Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (RHHVF)
OTHER OTC:RHHVF
Earnings Data
Report Date
Jan 29, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
11.39Last Year’s EPS
10.53Same Quarter Last Year
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call presented a strong performance in the Pharma segment, with significant growth in sales, profit, and key product performance. However, the Diagnostics segment faced challenges due to the China healthcare pricing reforms, and there were some mixed clinical trial results and safety concerns impacting specific treatments. Overall, the highlights in Pharma and financial management outweighed the challenges, resulting in a generally positive outlook, despite certain areas requiring attention.Company Guidance -
Q4 2025
Strong Pharma Growth
Pharma sales increased by 10% overall, with a specific growth of 11% in Q2. Core operating profit grew by 11% and core EPS increased by 12%. The bottom line performance was strong, with a core operating margin increase of 1.1 percentage points.
New Approvals and Pipeline Expansion
EU approval of Itovebi and U.S. approval of Susvimo. Four medicines have been moved into Phase III trials, with expectations for 8 to 11 medicines moving from Phase II to Phase III within the year.
Impressive Market Performance for Key Products
Vabysmo showed an 18% growth, Xolair exhibited strong momentum with over 60,000 patients in the U.S., and Polivy reached a 33% patient share in first-line DLBCL. Hemlibra also performed well with strong adoption across patient segments.
Positive Financial Management
R&D costs were kept flat, demonstrating efficient resource allocation and cost management. CHF 1 billion in savings achieved with a goal of CHF 3 billion by 2030 through various cost-cutting measures.
Diagnostics Growth Outside China
Excluding the impact of China reforms, Diagnostics grew 6%, with significant growth in North America and LatAm regions.
RHHVF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RHHVF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jul 24, 2025 | $329.54 | $333.95 | +1.34% |
Jan 30, 2025 | $302.03 | $306.21 | +1.38% |
Jul 25, 2024 | $301.39 | $306.44 | +1.68% |
Feb 01, 2024 | $263.35 | $252.07 | -4.28% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Roche Holding AG (RHHVF) report earnings?
Roche Holding AG (RHHVF) is schdueled to report earning on Jan 29, 2026, Before Open (Confirmed).
What is Roche Holding AG (RHHVF) earnings time?
Roche Holding AG (RHHVF) earnings time is at Jan 29, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RHHVF EPS forecast?
RHHVF EPS forecast for the fiscal quarter 2025 (Q4) is 11.39.